Xevinapant is a potent, oral, small-molecule IAP inhibitor that blocks XIAP and cIAP1/2, restoring cancer cell sensitivity to apoptosis and, thereby, is thought to enhance the effects of anticancer treatments such as chemotherapy and radiotherapy [61–63]. The gene discussed is XIAP; the disease is cancer.